|
|
Small and Mid Cap Clinical and Regulatory Conference:
Effectively Developing and Commercializing Drugs In Today's Environment
August 4, 2008
Oppenheimer's first annual Small and Mid Cap Clinical and Regulatory Conference will take place August 4, 2008 at Oppenheimer's 300 Madison Avenue offices in New York City.
The FDA Amendments Act of 2007 (FDAAA), passed in September of last year, is viewed as an attempt to reshape the regulatory environment in the United States after several years of negative publicity for the Agency. Accompanying the act are new requirements for regulatory approval, post-approval safety monitoring, and DTC advertising that must be considered by investors when weighing the risks of clinical development programs and the likelihood of reimbursement from private payers and government agencies. We believe our conference will provide a unique forum to gain insights about the dynamics of current regulatory environment from companies operating in this space.
Top clinical development and regulatory management from approximately 12 publicly traded small and mid cap biotechnology companies will give presentations on their experiences with the different phases of drug development and commercialization, including:
- Conducting mid-stage clinical trials with an eye towards regulatory approval
- Planning a pivotal clinical trial program
- Working with the FDA during the regulatory review process
- Planning for commercialization and launching of a new drug
In addition to company presentations, company representatives and independent regulatory and drug reimbursement experts will participate in panel discussions on drug development and commercialization. Companies will also be available for 1-on-1 meetings with institutional investors.
All conferences are for institutional clients of Oppenheimer & Co. Inc. and are by invitation only. For more information, please contact your Oppenheimer & Co. Inc. institutional sales representative.
|
|
|
|
